• Browse Industries
• Health Care

• FDLI SmartBrief
• News
• Press Releases
• SmartBlogs
• Topics
• FDA
• Generic drugs
• Medical devices
• Nutrition
• Stem Cells
• Vaccines
• Jobs
• View Job Listings
• Post a Job
• Job Listings FAQ's
• Most Clicked Stories
• FDLI News
• FDLI Reader Polls
• Archive
• RSS

• Find/Post Jobs

• Partner With Us

• Advertise

• About SmartBrief

• Reader Polls

FDA advisers to decide on continued sale of 2 pain drugs

An FDA panel is expected to decide today whether painkillers Darvon and Darvocet should be pulled from the market because of concerns about their addictive effects. The drugs contain propoxyphene, which has been linked to 3,028 cases of adverse events between 1957 and Sept. 24, 2008, according to the FDA. The agency sought advice from independent experts in response to a petition and lawsuit from advocacy group Public Citizen.

CNNMoney.com | 01/29

This story published in FDLI SmartBrief on 01/30/2009

Get stories like these delivered daily for FREE:

FDLI SmartBrief Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more